Depressive Disorder Clinical Trial
— AMTL-BEOfficial title:
Bioavailability Study of Amitriptyline Hydrochloride Tablets
Verified date | January 2019 |
Source | First Affiliated Hospital of Zhejiang University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Main Objectives: In Chinese healthy subjects under both fasting and postprandial conditions,
amitriptyline hydrochloride tablets (size: 25 mg) produced by Sandoz Inc., US Orange Book,
were used as reference preparations. A single-dose oral reference preparation and
amitriptyline hydrochloride tablets (size: 25 mg) produced by Hunan Dongting Pharmaceutical
Co., Ltd., and the calculation of the drug by the time course of amitriptyline and its active
metabolite, nortriptyline, in vivo The kinetic parameters were compared, and the relative
bioavailability of the two was compared to evaluate bioequivalence, which provided the basis
for the bioequivalence study of amitriptyline hydrochloride tablets by Hunan Dongting
Pharmaceutical Co., Ltd.
Secondary Objective: To monitor the safety of fasting and postprandial oral test and
reference preparations.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 31, 2019 |
Est. primary completion date | January 31, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Age 18-45 years old (including 18 and 45 years old), both male and female; 2. Male subjects weigh more than 50kg (including 50kg) and female subjects weigh more than 45kg (including 45kg); Body mass index [BMI = body weight (kg)/height (m)2] is in the range of 19 to 26 kg/m2; 3. According to past medical history, comprehensive physical examination and prescribed laboratory tests, the investigator determined that Healthy subjects; 4. Women of childbearing age have a negative blood pregnancy test and are effective from 14 days before dosing to 6 months after the end of study Appropriate contraceptive measures; 5. Male volunteers must take effective and appropriate 14 days before dosing until 6 months after the end of the study. The contraceptive measures and agrees not to perform sperm donation within six months from the administration until the end of the study; 6. Fully understand the purpose of the test, the nature of the test, the study procedures, and possible adverse reactions. Willing to participate in the trial and sign the informed consent form (the process of obtaining the informed consent accords with GCP regulations); 7. Communicate well with the researcher, follow the requirements of the entire study, and be willing to stay in the Phase I clinical research ward as required. Exclusion Criteria: 1. Can not tolerate venipuncture, who have a history of dizziness and pinching blood; 2. Clearly have a history of allergies to the drug ingredients or similar species or to two or more other drugs Sensitive history and highly sensitive to food and environmental substances; 3. Have a history of any serious clinical illness, including but not limited to digestive system, cardiovascular system, respiratory system, Urinary system, musculoskeletal system, endocrine system, neuropsychiatric system, blood system, immune system Patients with a history of diseases and metabolic disorders; 4. Laboratory tests (blood routine, urine routine, blood chemistry, etc.) and chest X-ray and ECG within 2 weeks before the test Those who have abnormal clinical findings 5. Hematological screening (HIV antibody or HBV surface antigen or HCV antibody or TP antibody) positive; 6. women who are breastfeeding, pregnant or plan to become pregnant recently; 7. Female subjects are in lactation or positive pregnancy test during the screening period or during the trial; 8. Male and female subjects who have not taken effective contraception or whose spouse plans to have children within six months; 9. Persons with mental or legal disabilities; 10. Screening for history of prescription drug abuse and/or history of illegal drug abuse within the first 6 months of screening; 11. A person who has a history of alcohol abuse within the first 6 months of screening, ie drinking more than 14 units of alcohol per week (1 unit = 12 ounces or 360 mL beer, 1.5 ounces or 45 mL alcohol 40% spirits, 5 ounces or 150mL wine); 12. Smoke more than 5 cigarettes per day within 6 months before screening; 13. positive for substance abuse screening or alcohol testing; 14. Those with a history of hospitalization or surgery within 3 months prior to screening (excluding appendicitis); 15. Participate in other drug clinical trials within 3 months before screening; 16. Have blood donation or acute blood loss history (=400 mL) within the first 2 months of screening or 1 after the end of the trial Intended to donate blood during the month; 17. Those who used any other medicine within 2 weeks before the test (prescription drugs, non-prescription drugs, any vitamins) Products or herbs); 18. Drink more than 1L of tea, coffee, and/or caffeinated beverages daily; 19. Those who have special dietary requirements and cannot accept a unified diet; 20. Those who are lactose intolerant (have been drinking milk diarrhea); 21. Those who do not understand the content of the informed consent and those who do not meet the criteria for the trial enrollment; 22. Subjects are poorly adhered to, or the investigator believes there are any individuals who are unfit to participate in the trial. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital,ZheJiang Univercity | Hanzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital of Zhejiang University | Hunan DongtingPharm.Co.Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax | Maximum Observed Plasma Concentration for amitriptyline | 144 hours post-dose on Day 1,22 | |
Primary | Tmax | Time to Reach the Maximum Plasma Concentration | 144 hours post-dose on Day 1,22 | |
Primary | AUC(0-inf) | Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for amitriptyline | 144 hours post-dose on Day 1,22 | |
Primary | AUC(0-144h) | Area Under the Plasma Concentration-Time Curve From Time 0 to 36 hours Postdose for amitriptyline | 144 hours post-dose on Day 1,22 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01316926 -
Paxil CR Bioequivalence Study Brazil
|
Phase 1 | |
Recruiting |
NCT06187454 -
Transcranial Direct Current Stimulation for Depression
|
N/A | |
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT05768126 -
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
|
Phase 4 | |
Completed |
NCT03219879 -
Telephone-administered Relapse Prevention for Depression
|
N/A | |
Recruiting |
NCT06038721 -
Unified Protocol: Community Connections
|
N/A | |
Completed |
NCT03043560 -
Study to Treat Major Depressive Disorder With a New Medication
|
Phase 2 | |
Completed |
NCT04091139 -
Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
|
Phase 2/Phase 3 | |
Completed |
NCT00069459 -
Seasonal Affective Depression (SAD) Study
|
Phase 1 | |
Recruiting |
NCT05503966 -
Combining Antidepressants and Attention Bias Modification in Depression
|
N/A | |
Recruiting |
NCT03001245 -
Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents
|
N/A | |
Completed |
NCT02939560 -
TMS for Adults With Autism and Depression
|
N/A | |
Completed |
NCT02542891 -
European Comparative Effectiveness Research on Internet-based Depression Treatment
|
N/A | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Withdrawn |
NCT02238730 -
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
|
N/A | |
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
Completed |
NCT01597661 -
Bupropion & Cardio Birth Defect (Slone)
|
N/A | |
Completed |
NCT01407575 -
Buprenorphine for Treatment Resistant Depression
|
Phase 3 | |
Completed |
NCT01093053 -
Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations
|
N/A |